|Day Low/High||9.84 / 10.17|
|52 Wk Low/High||8.42 / 23.98|
Results Expected in the First Half of 2017
Initial Results Expected in Late 2016/Early 2017
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in OncoMed Pharmaceuticals Inc. , where a total volume of 510 contracts has been traded thus far today, a contract volume which is representative of approximately 51,000 underlying shares (given that every 1 contract represents 100 underlying shares).
The most recent short interest data has been released for the 07/29/2016 settlement date, which shows a 350,042 share increase in total short interest for OncoMed Pharmaceuticals Inc. , to 2,303,320, an increase of 17.92% since 07/15/2016.
Investors considering a purchase of OncoMed Pharmaceuticals Inc. stock, but tentative about paying the going market price of $12.31/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Biotech stocks remain pressured following the recent Brexit vote, which will make investing in these already highly volatile stocks even trickier. But there are opportunities too.
Investors eyeing a purchase of OncoMed Pharmaceuticals Inc. shares, but cautious about paying the going market price of $14.89/share, might benefit from considering selling puts among the alternative strategies at their disposal.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.